Related references
Note: Only part of the references are listed.The nine hole peg test as an outcome measure in progressive MS trials
Marcus W. Koch et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)
The timed 25-foot walk in a large cohort of multiple sclerosis patients
Anissa Kalinowski et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
An enrichment strategy for clinical trials in SPMS
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Repurposing Domperidone in Secondary Progressive Multiple Sclerosis A Simon 2-Stage Phase 2 Futility Trial
Marcus W. Koch et al.
NEUROLOGY (2021)
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis
Marcus W. Koch et al.
NEUROLOGY (2021)
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
Marcus W. Koch et al.
NEUROLOGY (2021)
Repurposing Domperidone in Secondary Progressive Multiple Sclerosis
Marcus W. Koch et al.
NEUROLOGY (2021)
Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
L. V. A. E. Bosma et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Disability as an outcome in MS clinical trials
G. C. Ebers et al.
NEUROLOGY (2008)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis
J. J. Kragt et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Quantitative functional measures in MS: What is a reliable change?
SR Schwid et al.
NEUROLOGY (2002)